Circulating cardiovascular proteomic associations with genetics and disease

Kathryn A McGurk,Lara Curran,Arunashis Sau,Fu Siong Ng,James Ware,Declan P O'Regan
DOI: https://doi.org/10.1101/2024.10.18.24315790
2024-10-19
Abstract:Background: The analysis of the circulating proteome can identify translational modifiers and biomarkers of disease expressivity and severity at a particular sampling time point. Focused analyses are required to understand the relationships between protein measures of interest and cardiovascular disease and whether they mediate causal relationships between cardiovascular risk factors and disease development. Methods: To understand the relationships between circulating biomarkers and genetic variants, medications, anthropometric traits, lifestyle factors, imaging-derived measures, and diagnoses of cardiovascular disease, we analysed measures of nine plasma proteins with a priori roles in genetic and structural cardiovascular disease or treatment pathways (ACE2, ACTA2, ACTN4, BAG3, BNP, CDKN1A, NOTCH1, NT-proBNP, and TNNI3) from the Pharma Proteomics Project of the UK Biobank cohort (over 45,000 participants sampled at recruitment). Results: We identified significant variability in circulating proteins with age, sex, ancestry, alcohol intake, smoking, and medication intake. Phenome-wide association studies highlighted the range of cardiovascular clinical features with relationships to protein levels. Genome-wide genetic association studies identified variants near GCKR, APOE, and SERPINA1, that modified multiple circulating protein levels (BAG3, CDKN1A, and/or NOTCH1). NT-proBNP and BNP levels associated with variants in BAG3. ACE2 levels were increased with a diagnosis of hypertension or diabetes and were influenced by variants in genes associated with diabetes (HNF1A, HNF4A). Two-sample Mendelian randomisation identified ACE2 as protective for systolic blood pressure and Type-2 diabetes. Conclusions: The results from this observational study provide evidence for ACE2 as a protective biomarker that is increased with a diagnosis of hypertension and diabetes. This suggests that ACE2 stimulation may provide additional protection from these cardiovascular diseases. This study provides an improved understanding of the circulating pathways depicting cardiovascular disease dynamics.
What problem does this paper attempt to address?
This paper aims to explore the relationships between circulating cardiovascular proteomics and genetic variation, drug use, anthropometric characteristics, lifestyle factors, imaging - derived indicators, and the diagnosis of cardiovascular diseases. Specifically, the study analyzed nine plasma proteins (ACE2, ACTA2, ACTN4, BAG3, BNP, CDKN1A, NOTCH1, NT - proBNP, and TNNI3) in more than 45,000 participants in the UK Biobank. These proteins play important roles in hereditary and structural cardiovascular diseases or treatment pathways to identify their relationships with cardiovascular diseases and to explore whether these proteins mediate the causal relationships between cardiovascular risk factors and disease development. Research methods include: 1. **Data analysis**: Analyzed the relationships between protein levels and factors such as age, gender, ethnicity, alcohol intake, smoking status, and drug use. 2. **Genome - wide association study (GWAS)**: Conducted a genome - wide association study to identify genetic variations that affect these protein levels. 3. **Mendelian randomization analysis**: Used a two - sample Mendelian randomization method to evaluate the causal effects of protein levels on blood pressure and type 2 diabetes. 4. **Clinical endpoint analysis**: Analyzed the relationships between protein levels and the clinical characteristics of cardiovascular diseases through cardiac magnetic resonance imaging (CMR) and electrocardiogram (ECG) data. Main conclusions include: - Significant variability was found between circulating protein levels and age, gender, ethnicity, alcohol intake, smoking status, and drug use. - Through genome - wide association studies, genetic variations that affect multiple circulating protein levels were identified, such as variations near GCKR, APOE, and SERPINA1. - Mendelian randomization analysis showed that ACE2 levels have a protective effect on systolic blood pressure and type 2 diabetes. - The research results indicate that ACE2 levels increase in patients with hypertension and diabetes, which may mean that ACE2 stimulation can provide additional cardiovascular protection. In conclusion, this study provides new insights into how circulating cardiovascular proteomics depicts the dynamics of cardiovascular diseases, especially the role of ACE2 as a protective biomarker.